The pathway most affected by MTA1 overexpression in the PTEN-loss prostate was the mTORC1 (hereafter mTOR) pathway (Figure 2B, Supplementary Table S3), which is known to be aberrantly activated in castration-resistant prostate cancer [33] and advanced prostate cancer with a reduced expression of PTEN [14]. This evidence concerns the gene PTEN and prostate cancer.